

Quarterly Update - Q3 2025

Protea Fund

Veritas Core Equity
with Fixed Income

30 September 2025



Protea Fund – Veritas Core Equity with Fixed Income

Performance

	Q3 2025	YTD	2024	2023	Last 5 years	Since 31 Dec 2018 ¹
Protea Fund - Veritas CEFI (Acc)²	0.3%	-2.9%	9.6%	12.3%	32.2%	64.3%
UK CPI +3% ³	1.3%	5.3%	5.6%	6.9%	44.0%	52.5%
UK CPI ³	0.6%	3.0%	2.6%	3.9%	28.1%	30.5%
Peer Group ⁴	5.1%	6.8%	7.9%	7.2%	31.0%	47.0%
MSCI AC World Equity Index (£) ⁵	9.5%	10.2%	19.6%	15.3%	81.2%	129.1%
FTSE All-Share Index (£) ⁵	6.9%	16.6%	9.5%	7.9%	84.1%	75.7%
Inv. Grade Corporate Bonds (1-10Y) ⁵	1.2%	5.1%	4.4%	9.2%	5.8%	16.9%


Equity sectors ⁶	% Weight	Names
Information Technology	16.6%	Accenture, Amphenol, Cadence Design Systems, Intuit, Keyence Corp, Microsoft, Synopsys
Industrials	12.6%	AMETEK, Automatic Data Processing, Broadridge Financial Solutions, Bunzl, Experian, RELX, Verisk Analytics
Financials	9.9%	Fiserv, London Stock Exchange Group, Marsh & McLennan, Mastercard
Health Care	9.7%	Intuitive Surgical, Labcorp Holdings, Roche, Sonova, Thermo Fisher Scientific
Consumer Discretionary	6.9%	Amazon, Next, Tractor Supply
Communication Services	2.5%	Alphabet
Materials	2.4%	Avery Dennison, DSM-Firmenich
Consumer Staples	1.4%	Kerry

Fund Performance figures are in Sterling, total returns with net dividends reinvested.¹Performance since month of inception. ²Protea Fund returns are net of all fees and costs.³UK CPI are the most recent figures at the time of publication and obtained from external sources. UK CPI +3% figures are calculated internally using methodology that may differ from external counterparties. ⁴The ARC £ Steady Growth Index initial estimates are subject to revision. ⁵All Indices are gross of fees. Where shown Inv. Grade Corporate Bonds (1-10Y) refers to BofA ML index.⁶Global Industry Classification Standard (GICS®), as determined by MSCI Inc. and S&P Global Market Intelligence, is used for sector classification of the securities and is shown only for comparability purposes. Source: Pictet, Bloomberg, Factset. All figures are unaudited and subject to change. Totals may not add precisely due to rounding.

Investment Mandate

Objective	To protect our clients' assets and grow them well above inflation over the long-term
Risk Profile	Medium risk with a strategic asset allocation of 65% in equities and 35% in cash/bonds

Asset Allocation (% of Portfolio)



Morningstar ESG Risk Rating™



Out of 8,445 Aggressive Allocation funds as at 30 September 2025. Based on 98% of eligible corporate AUM and long positions only. Sustainalytics provides company-level analysis used in the calculation of Morningstar's Historical ESG Risk Score.

Quarterly Update

Investment commentary

Everything everywhere all at once

It has been a challenging environment. Naturally, we are disappointed with the performance of the fund in the year to date. Before we get into the specifics, it is worth taking a step back. As the CEO of a S&P 500 company recently summed things up succinctly:

“In every boardroom and every industry, our clients are not facing a single challenge. They are facing **everything at once** – economic volatility, geopolitical complexity and major shifts in customer behaviour.”

The dislocation since the pandemic is still being felt in the form of inflation, higher interest rates and higher levels of government debt. This is feeding into rising protectionism in the form of tariffs. Add in technological disruption (particularly from AI) and the result is that the baseline level of risk in the world has risen. The headwinds companies face have intensified, hampering growth.

Lower economic growth means finding *enough* growth – and *resilient* growth – is more demanding than it once was. In retrospect, we should have been even more questioning of companies' guidance for future growth. This is why we are making changes, with **Align Technology** and **UnitedHealth Group** (hitherto a stalwart portfolio holding) making way for new ideas in the fund.

The markets remain fixated on a handful of AI-related companies, such as Nvidia and Meta. They offer growth, yes. But at any cost? European banks and pure-play defence companies are also in favour. These parts of the market are cyclical and typically do not provide the durable growth that we look for. But with geopolitical risk and defence spending rising, we do hold **AMETEK** and **Amphenol**. Their instrumentation and electrical components will be in increasing demand.

It is sometimes worth stating the obvious: in the short term, share prices don't always reflect the true value of a growing business. This creates opportunities to buy companies with strong tailwinds that position us well for the future. We have recently added **Verisk Analytics**, a leading provider of data and decision-making tools that enable insurers to price risk correctly. It's a good business to own in a world of rising risk.

Companies we own *are* growing and *are* delivering free cash flow. These are essential ingredients for delivering resilient growth, whatever the weather, and inflation-plus returns over the long term.

Performance

+ **Alphabet's** strong quarterly results (total revenue up 14%) set the stage for further share price gains during the quarter. With its core search business remaining steady, Google continues to defy concerns that it is vulnerable to AI disruption. Across its wider business, Alphabet is an innovation powerhouse in multiple areas, from Google Cloud to robotics (Waymo robotaxis), quantum computing (Willow chips) and AI (Nano Banana AI image editor). Initial outcomes in its US anti-trust cases are better than expected.

+ **Thermo Fisher Scientific's** quarterly results exceeded expectations for revenues and earnings per share, and full-year guidance was increased. Investors also welcomed the management's proactive approach to addressing their concerns about the outlook for Thermo's core biopharmaceutical market, outlining the company's accelerating cost efficiency and setting realistic multi-year targets. The US political environment began to ease in Q3 with National Institutes of Health grants (a major source of biomedical research funding) resuming. This was a shift from previous quarters and served as a reminder of the virtue of patience and cool heads during short-term volatility.

- Despite delivering solid results, **London Stock Exchange Group (LSEG)** has been caught in an indiscriminate pullback in information services stocks believed to be susceptible to AI disruption. We believe this is misguided in LSEG's case:

Quarterly Update

its customers are unlikely to swap mission-critical LSEG data feeds for unproven and potentially unreliable AI-sourced data. Meanwhile, LSEG continues to embed its own AI tools in partnership with Microsoft.

- **Fiserv** continues to suffer from weak investor sentiment after marginally missing revenue expectations early in the year. The company is growing its revenues at 9% per annum, with its core businesses providing good recurring revenues. Clover, its point-of-sale solution, is a substantial growth opportunity. A recovery in the share price needs better communication with investors from Fiserv's new leadership and evidence that future growth opportunities are being captured.

Transactions

We introduced a position in **Verisk Analytics**, a leading data analytics company that enables insurers to price risk. Verisk is a mission-critical supplier to insurance companies, providing predictive analytics, risk assessment and solutions that improve underwriting, pricing, claims management and regulatory compliance.

We continued to build the position in **RELX**, a global provider of data and analytical tools with a front-footed approach to integrating AI tools. These enable its users in sectors such as insurance, legal and healthcare to be more productive.

Align Technology continues to be the undisputed leader in clear dental aligners. However, our continual channel checking, including with international orthodontists in the real world, highlighted Align's continuing reliance on orthodontists to distribute its products makes it uncertain how quickly the shift to clear aligners from traditional wires and brackets will occur.

UnitedHealth Group's difficulties stem from a rare operational error in pricing new business, compounded by material management changes and negative

press coverage. Its most recent results announcing lower guidance and further management changes underscore the uncertainty as to when it will return to growth. We reallocated sale proceeds across existing fund holdings that offer better places to grow our clients' capital ahead of inflation.

Non-equity holdings

The fixed income market continues to offer opportunities to purchase high-quality bonds with a yield to maturity of more than 4%. With equities the engine for long-term growth, this relative security is a valuable balance in the fund.

With inflation proving stickier than expected, we increased exposure to index-linked bonds. The index-linked market is offering real yields not seen since the 2000s, in some cases equivalent to inflation plus 1-2% for more than five years, backed by the government.

The fund's gold position has continued to benefit the portfolio. Gold has reached new all-time highs in response to the greater geopolitical and economic uncertainty.

Portfolio activity – engagement

Demonstrating the hard economic benefits of reducing carbon emissions is important. Some initiatives do show immediate financial results, benefitting companies and their shareholders. By switching to LED lights, **LSEG** saves £9m per year at its Bangalore offices and **Next** saves almost £4m in its stores. On-site solar panels save **Avery Dennison** \$900k each year.

We have met our 2030 carbon intensity reduction targets for our in-scope assets. More information is available in our 2024 [Climate Report](#), together with examples of our work with companies to help reduce emissions.

Quarterly Update

Top 10 Equity Holdings

Holding	% Weight
Experian	3.3
Microsoft	3.3
Mastercard	3.1
Intuit	2.8
Marsh & McLennan	2.8
Amazon	2.8
Tractor Supply	2.6
Labcorp Holdings	2.6
Cadence Design Systems	2.5
London Stock Exchange Group	2.5
Top 10 Equity Total	28.2

Important Information

Fund manager	Navera Investment Management Limited
Ongoing charges	0.75%
Inception date	14th December 2018
Fund size	GBP 714.6m
Pricing	Daily
Base currency	GBP
Fund type	UCITS
Structure	SICAV
Domicile	Luxembourg
Tax status	UK Reporting Fund
SFDR classification	Article 8
Custodian bank	Pictet & Cie (Europe) SA
Dividend paid	January / July
Previous dividend rate (January 2025 / July 2025)	GBP 1.00 / 0.88
ISIN (Dis/Acc)	LU1883344829 / LU1883345123

Navera Investment Management Limited

Riverside House, 2a Southwark Bridge Road, London, SE1 9HA

Switchboard: + 44 20 3740 8350

Authorised and regulated by the Financial Conduct Authority

Registered in England & Wales. Reg. No: 12516583

www.naverainvestment.com

Navera Investment Management Limited is authorised and regulated by the Financial Conduct Authority in the conduct of its investment business. It is registered under number 923827. For more information click on www.fca.org.uk. Navera Investment Management Limited is a discretionary investment manager and does not offer investment advice; and no information contained within this document should be construed as such. If you are in doubt, you should seek advice from a financial adviser.

Disclosure

Investors should consult the KIID and fund prospectus before making any purchase. They can be downloaded from www.naverainvestment.com/fund-library/.

Past performance should not be seen as an indication of future performance.

The value of investments and the income from them may fluctuate and are not guaranteed. Investors may not get back the whole amount they have invested.

Changes in rates of exchange between currencies may cause the value of investments to diminish or to increase.

Reliance should not be placed on the views and information in this document when taking individual investment and/or strategic decisions. Opinions, estimates, forecasts, projections and statements of financial market trends are based on market conditions at the date of the publication, constitute our judgment and are subject to change without notice. There can be no guarantee they will be met. This is a marketing communication according to ESMA guidelines. For more information please refer to our fund library on our website.

The Protea Fund - Veritas Core Equity with Fixed Income does not have a sustainability investment objective.

Sources

MSCI: The MSCI information may only be used for your internal use, may not be reproduced or disseminated in any form and may not be used as a basis for or a component of any financial instruments or products or indices. None of the MSCI information is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such.

London Stock Exchange Group plc and its group undertakings (collectively, the “LSE Group”). © LSE Group 2025. FTSE Russell is a trading name of certain of the LSE Group companies. “FTSE®” is a trade mark of the relevant LSE Group companies and is used by any other LSE Group company under license. All rights in the FTSE Russell indices or data vest in the relevant LSE Group company which owns the index or the data. Neither LSE Group nor its licensors accept any liability for any errors or omissions in the indices or data and no party may rely on any indices or data contained in this communication. No further distribution of data from the LSE Group is permitted without the relevant LSE Group company’s express written consent. The LSE Group does not promote, sponsor or endorse the content of this communication.

Morningstar®. All rights reserved. The information contained herein: 1) is proprietary to Morningstar and/ or its content providers; 2) may not be copied or attributed; and 3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

This fund and FundPartner Solutions (Europe) S.A are authorised and regulated by the Commission de Surveillance du Secteur Financier (CSSF).